Hidradenitis Suppurativa/Acne Inversa/Dissecting Terminal Hair Folliculitis

  • Gerd Plewig
  • Bodo Melnik
  • WenChieh Chen


What we today name dissecting terminal hair folliculitis (DTHF) has lurked in the literature under several synonyms, namely, Velpeau’s disease (1839), Verneuil’s disease (1854), hidradenitis destruens suppurativa (Pollitzer 1892), follicular occlusion triad (Pillibury, Shelley, and Kligman 1956), acne tetrad (Plewig and Kligman 1975), acne inversa (Plewig and Steger 1989), and dissecting terminal folliculitis (Plewig 2009). The most famous sufferer of acne inversa was Karl Marx.


  1. Abdennader S, Vignon-Pennamen MD, Hatchuel J, Reygagne P. Alopecic and aseptic nodules of the scalp (pseudocyst of the scalp): a prospective clinicopathological study of 15 cases. Dermatology. 2011;222:31–5.PubMedGoogle Scholar
  2. Acquacalda E, Roux CH, Albert C, et al. New onset of articular inflammatory manifestations in patients with hidradenitis suppurativa under treatment with infliximab. Joint Bone Spine. 2015;82:362–4.PubMedGoogle Scholar
  3. Alexis A, Heath CR, Halder RM. Folliculitis keloidalis nuchae and pseudofolliculitis barbae: are prevention and effective treatment within reach? Dermatol Clin. 2014;32:183–91.PubMedGoogle Scholar
  4. Ali N, Rosenblum MD. Regulatory T cells in skin. Immunology. 2017;152:372–81.PubMedPubMedCentralGoogle Scholar
  5. Ali N, Zirak B, Rodriguez RS, et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell. 2017;169:1119–29.e11.PubMedPubMedCentralGoogle Scholar
  6. Alzaga Fernandez AG, Demirci H, Darnley-Fisch DA, Steen DW. Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review. Cornea. 2010;29:1189–91.PubMedGoogle Scholar
  7. Badaoui A, Reygagne P, Cavelier-Balloy B, et al. Dissecting cellulitis of the scalp: a retrospective study of 51 patients and review of literature. Br J Dermatol. 2016;174:421–3.PubMedGoogle Scholar
  8. Barney RF. Dissecting cellulitis of the scalp (perifolliculitis capitis abscedens et suffodiens). Arch Dermatol Syph. 1931;23:503–18.Google Scholar
  9. Baumgärtner MA. Acne inversa. Genotypische und phänotypische Einflussfaktoren unter besonderer Berücksichtigung der molekulargenetischen Untersuchung der γ-Sekretase. Thesis, Medizinsche Fakulät der Ludwig-Maximilians Universität. München; 2017.Google Scholar
  10. Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839–46.PubMedGoogle Scholar
  11. Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol. 1996;135:721–5.PubMedGoogle Scholar
  12. Bolz S, Jappe U, Hartschuh W. Erfolgreiche kombinierte Isotretinoin und Dapson-Therapie bei Perifolliculitis capitis abscedens et suffodiens. J Dtsch Dermatol Ges. 2008;6:44–7.PubMedGoogle Scholar
  13. Brandt HR, Malheiros AP, Teixeira MG, Machado MC. Perifolliculitis capitis abscedens et suffodiens successfully controlled with infliximab. Br J Dermatol. 2008;159:506–7.PubMedGoogle Scholar
  14. Brănişteanu DE, Molodoi A, Ciobanu D, et al. The importance of histopathologic aspects in the diagnosis of dissecting cellulitis of the scalp. Rom J Morphol Embryol. 2009;50:719–24.PubMedGoogle Scholar
  15. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409–15.PubMedGoogle Scholar
  16. Calderón-Castrat X, Bancalari-Diaz D, Román-Curto C, et al. PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Br J Dermatol. 2016;175:194–8.PubMedGoogle Scholar
  17. Chen S, Mattei P, You J, et al. γ-Secretase mutation in an African American family with hidradenitis suppurativa. JAMA Dermatol. 2015;151:668–70.PubMedGoogle Scholar
  18. Chen W, Plewig G. Should hidradenitis suppurativa/acne inversa best be renamed as “dissecting terminal hair folliculitis”? Exp Dermatol. 2017;26:544–7.PubMedGoogle Scholar
  19. Chinnaiyan P, Tena LB, Brenner MJ, Welsh JS. Modern external beam radiation therapy for refractory dissecting cellulitis of the scalp. Br J Dermatol. 2005;152:777–9.PubMedGoogle Scholar
  20. Coggshall K, Farsani T, Ruben B, et al. Keratitis, ichthyosis, and deafness syndrome: a review of infectious and neoplastic complications. J Am Acad Dermatol. 2013;69:127–34.PubMedGoogle Scholar
  21. Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412–9.PubMedGoogle Scholar
  22. Curry SS, Gaither DH, King LE Jr. Squamous cell carcinoma arising in dissecting perifolliculitis of the scalp. A case report and review of secondary squamous cell carcinomas. J Am Acad Dermatol. 1981;4:673–8.PubMedGoogle Scholar
  23. Danby FW, Jemec GB, Marsch WC, von Laffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol. 2013;168:1034–9.PubMedGoogle Scholar
  24. Danby FW, Hazen PG, Boer J. New and traditional surgical approaches to hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S62–5.PubMedGoogle Scholar
  25. De Vita V, Melnik BC. Activated mTORC1 signaling: the common driving force of type 2 diabetes and hidradenitis suppurativa. J Am Acad Dermatol. 2018;78:e121.PubMedGoogle Scholar
  26. Denny G, Anadkat MJ. The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study. J Am Acad Dermatol. 2017;76:54–9.PubMedGoogle Scholar
  27. Dessinioti C, Zisimou C, Tzanetakou V, et al. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol. 2016;41:852–7.PubMedGoogle Scholar
  28. Duchatelet S, Miskinyte S, Join-Lambert O, et al. First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome. Br J Dermatol. 2015;173:610–2.PubMedGoogle Scholar
  29. East-Innis ADC, Stylianou K, Paolino A, Ho JD. Acne keloidalis nuchae: risk factors and associated disorders - a retrospective study. Int J Dermatol. 2017;56:828–32.PubMedGoogle Scholar
  30. Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 2016;152:429–34.PubMedGoogle Scholar
  31. Egeberg A, Jemec GBE, Kimball AB, et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J Invest Dermatol. 2017;137:1060–4.PubMedGoogle Scholar
  32. Esmat SM, Abdel Hay RM, Abu Zeid OM, Hosni HN. The efficacy of laser-assisted hair removal in the treatment of acne keloidalis nuchae; a pilot study. Eur J Dermatol. 2012;22:645–50.PubMedGoogle Scholar
  33. Fahrni GT, Vuille-Dit-Bille RN, Leu S, et al. Five-year follow-up and recurrence rates following surgery for acute and chronic pilonidal disease: a survey of 421 cases. Wounds. 2016;28:20–6.PubMedGoogle Scholar
  34. Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa: an unrecognized paradoxical effect of biologic agents used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74:1153–9.PubMedGoogle Scholar
  35. Feldmann K, Chatelain R, Kunte C, Plewig G. Cutis vertices gyrata-artige Acne inversa. In: Plewig G, Prinz J, editors. Fortschritte der praktischen Dermatologie und Venerologie 2002. Berlin: Springer; 2003. p. 657–9.Google Scholar
  36. Frew JW, Vekic DA, Woods J, Cains GD. A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa. Br J Dermatol. 2017;177:987–98.PubMedGoogle Scholar
  37. Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017a;153:760–4.PubMedPubMedCentralGoogle Scholar
  38. Garg A, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017b;77:118–22.PubMedGoogle Scholar
  39. Garg A, Papagermanos V, Midura M, Strunk A. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol. 2018a;178:709–14.PubMedGoogle Scholar
  40. Garg A, Wertenteil S, Baltz R, et al. Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender and age adjusted population analysis. J Invest Dermatol. 2018b;138:2152–6.PubMedGoogle Scholar
  41. Georgala S, Korfitis C, Ioannidou D, et al. Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin: case reports. Cutis. 2008;82:195–8.PubMedGoogle Scholar
  42. Glenn MJ, Bennett RG, Kelly AP. Acne keloidalis nuchae: treatment with excision and second-intention healing. J Am Acad Dermatol. 1995;33:243–6.PubMedGoogle Scholar
  43. Gloster HM Jr. The surgical management of extensive cases of acne keloidalis nuchae. Arch Dermatol. 2000;136:1376–9.PubMedGoogle Scholar
  44. Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70:699–703.PubMedGoogle Scholar
  45. Hoffman E. Perifolliculitis capitis abscedens et suffodiens: case presentation. Dermatol Z. 1908;15:122–3.Google Scholar
  46. Holzinger D, Fassl SK, de Jager W, et al. Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases. J Allergy Clin Immunol. 2015;136:1337–45.PubMedGoogle Scholar
  47. Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. 2016;136:1768–80.PubMedGoogle Scholar
  48. Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174:970–8.PubMedPubMedCentralGoogle Scholar
  49. Ingram JR, Jenkins-Jones S, Knipe DW, et al. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178:917–24.PubMedGoogle Scholar
  50. Janjua SA, Iftikhar N, Pastar Z, Hosler GA. Keratosis follicularis spinulosa decalvans associated with acne keloidalis nuchae and tufted hair folliculitis. Am J Clin Dermatol. 2008;9:137–40.PubMedGoogle Scholar
  51. Kantor GHR, Ratz JL, Wheeland RG. Treatment of acne keloidalis nuchae with carbon dioxide laser. J Am Acad Dermatol. 1986;14:263–7.PubMedGoogle Scholar
  52. Kelly G, Sweeney CM, Fitzgerald R, et al. Vitamin D status in hidradenitis suppurativa. Br J Dermatol. 2014;170:1379–80.PubMedGoogle Scholar
  53. Khanna A, Rombeau JL. Pilonidal disease. Clin Colon Rectal Surg. 2011;24:46–53.PubMedPubMedCentralGoogle Scholar
  54. Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Hairdressing and the prevalence of scalp disease in African adults. Br J Dermatol. 2007;157:981–98.PubMedGoogle Scholar
  55. Kohn M. Über die sogenannte Framboesia und mehrere andere Arten von papillären Neubildungen der Haut. Vier Fälle von Dermatitis papillomatosa capillitii. (Framboesia non syphilitica capillitii). Arch Dermatol Syph. 1869;1:382–423.Google Scholar
  56. Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232:687–91.PubMedGoogle Scholar
  57. Kurokawa I, Nishijima S, Kusumoto K, et al. Immunohistochemical study of cytokeratins in hidradenitis suppurativa (acne inversa). J Int Med Res. 2002a;30:131–6.PubMedGoogle Scholar
  58. Kurokawa I, Nishijima S, Suzuki K, et al. Cytokeratin expression in pilonidal sinus. Br J Dermatol. 2002b;146:409–13.PubMedGoogle Scholar
  59. Kurokawa I, Hayashi N, Japan Acne Research Society. Questionnaire surveillance of hidradenitis suppurativa in Japan. J Dermatol. 2015;42:747–9.PubMedGoogle Scholar
  60. Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010;220:147–53.PubMedGoogle Scholar
  61. Lehmann P. Cutis verticis gyrata-like acne inversa. Kombinierte medikamentöse und chirurgische Therapie. Hautarzt. 2009;60:328–30.PubMedGoogle Scholar
  62. Lim DT, James NM, Hassan S, Khan MA. Spondyloarthritis associated with acne conglobata, hidradenitis suppurativa and dissecting cellulitis of the scalp: a review with illustrative cases. Curr Rheumatol Rep. 2013;15:346.PubMedGoogle Scholar
  63. Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc. 1997;72:611–5.PubMedGoogle Scholar
  64. Losanoff JE, Sochaki P, Khoury N, et al. Squamous cell carcinoma complicating chronic suppurative hydradenitis. Am Surg. 2011;77:1449–53.PubMedGoogle Scholar
  65. Maryanovich M, Frenette PS. T-Regulating hair follicle stem cells. Immunity. 2017;46:979–81.PubMedGoogle Scholar
  66. Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149:762–4.PubMedGoogle Scholar
  67. McMillan K. Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States. Am J Epidemiol. 2014;179:1477–83.PubMedGoogle Scholar
  68. Mehdizadeh A, Hazen PG, Bechara FG, et al. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(5 Suppl 1):S70–7.PubMedGoogle Scholar
  69. Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol. 2013;22:172–7.PubMedGoogle Scholar
  70. Melnik BC, John SM, Chen W, Plewig G. Th17/Treg imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking, and autoimmune comorbidities. Br J Dermatol. 2018;179:260–72.Google Scholar
  71. Miller IM, Ellervik C, Vinding GR, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014;150:1273–80.PubMedGoogle Scholar
  72. Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol. 2017;137:2389–95.PubMedGoogle Scholar
  73. Mota F, Machado S, Selores M. Hidradenitis suppurativa in children treated with finasteride-a case series. Pediatr Dermatol. 2017;34:578–83.PubMedGoogle Scholar
  74. Murao K, Fukumoto D, Kubo Y. Squamous cell carcinoma of the scalp associated with human papillomavirus type 16. Eur J Dermatol. 2011;21:1005–6.PubMedGoogle Scholar
  75. Navarini AA, Trüeb RM. 3 Cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease. Arch Dermatol. 2010;146:517–20.PubMedGoogle Scholar
  76. Ogunbiyi A, Adedokun B. Perceived aetiological factors of folliculitis keloidalis nuchae (acne keloidalis) and treatment options among Nigerian men. Br J Dermatol. 2015;173 Suppl 2:22–5.PubMedGoogle Scholar
  77. Pagliarello C, Fabrizi G, Feliciani C, Di Nuzzo S. Cryoinsufflation for Hurley stage II hidradenitis suppurativa: a useful treatment option when systemic therapies should be avoided. JAMA Dermatol. 2014;150:765–6.PubMedGoogle Scholar
  78. Perng P, Zampella JG, Okoye GA. Management of hidradenitis suppurativa in pregnancy. J Am Acad Dermatol. 2017;76:979–89.PubMedGoogle Scholar
  79. Pillsbury DM, Shelley WB, Kligman AM. A manual of cutaneous medicine. Philadelphia: Saunders; 1965.Google Scholar
  80. Plewig G, Kligman AM. Acne. Morphogenesis and treatment. Berlin: Springer; 1975.Google Scholar
  81. Plewig G, Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G, editors. Acne and related disorders. London: Dunitz; 1989. p. 345–57.Google Scholar
  82. Pollitzer S. Hidradenitis destruens suppurativa. J Cutan Genitourin Di. 1892;10:9–24.Google Scholar
  83. Posch C, Monshi B, Quint T, et al. The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): setrospective analysis of 74 patients. J Am Acad Dermatol. 2017;77:123–129.e5.PubMedGoogle Scholar
  84. Reeder VJ, Mahan MG, Hamzavi IH. Ethnicity and hidradenitis suppurativa. J Invest Dermatol. 2014;134:2842–3.PubMedGoogle Scholar
  85. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.PubMedGoogle Scholar
  86. Sbidian E, Hotz C, Seneschal J, et al. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. Br J Dermatol. 2016;174:667–70.PubMedGoogle Scholar
  87. Scheinfeld N. Dissecting cellulitis (perifolliculitis capitis abscedens et suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa. Dermatol Online J. 2014;20:22692.PubMedGoogle Scholar
  88. Scheinfeld N. Hidradenitis suppurativa in prepubescent and pubescent children. Clin Dermatol. 2015;33:316–9.PubMedGoogle Scholar
  89. Schneider MR, Paus R. Deciphering the functions of the hair follicle infundibulum in skin physiology and disease. Cell Tissue Res. 2014;358:697–704.PubMedGoogle Scholar
  90. Schrader AM, Deckers IE, van der Zee HH, et al. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71:460–7.PubMedGoogle Scholar
  91. Shahi V, Alikhan A, Vazquez BG, et al. Prevalence of hidradenitis suppurativa: a population-based study in Olmsted County, Minnesota. Dermatology. 2014;229:154–8.PubMedPubMedCentralGoogle Scholar
  92. Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173:464–70.PubMedGoogle Scholar
  93. Shalom G, Freud T, Ben Yakov G, et al. Hidradenitis suppurativa and inflammatory bowel disease: a cross-sectional study of 3,207 patients. J Invest Dermatol. 2016;136:1716–8.PubMedGoogle Scholar
  94. Shavit E, Dreiher J, Freud T, et al. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:371–6.PubMedGoogle Scholar
  95. Shuster S. The nature and consequence of Karl Marx’s skin disease. Br J Dermatol. 2008;158:1–3.PubMedGoogle Scholar
  96. Sonbol H, Duchatelet S, Miskinyte S, et al. PASH syndrome a disease with genetic heterogeneity. Br J Dermatol. 2018;178:e17–8.PubMedGoogle Scholar
  97. Sperling LC, Homoky C, Pratt L, Sau P. Acne keloidalis is a form of primary scarring alopecia. Arch Dermatol. 2000;136:479–84.PubMedGoogle Scholar
  98. Spitzer L. Dermatitis follicularis et perifollicularis conglobata. (Hierzu Taf. III, IV). Dermatol Z. 1903;10:109–20.Google Scholar
  99. Su HJ, Cheng AY, Liu CH, et al. Primary scarring alopecia: a retrospective study of 89 patients in Taiwan. J Dermatol. 2018;45:450–5.PubMedGoogle Scholar
  100. Thomi R, Cazzaniga S, Seyed Jafari SM, et al. Association of hidradenitis suppurativa with T helper 1/T helper 17 phenotypes: a semantic map analysis. JAMA Dermatol. 2018;154:592–5.PubMedPubMedCentralGoogle Scholar
  101. Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152:52–9.PubMedGoogle Scholar
  102. Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173:1142–55.PubMedGoogle Scholar
  103. van der Zee HH, de Winter K, van der Woude CJ, Prens EP. The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol. 2014;171:673–5.PubMedGoogle Scholar
  104. Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97–103.PubMedGoogle Scholar
  105. Verdolini R, Clayton N, Smith A, et al. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27:1101–8.PubMedGoogle Scholar
  106. von Laffert M, Stadie V, Ulrich J, et al. Morphology of pilonidal sinus disease: some evidence of its being a unilocalized type of hidradenitis suppurativa. Dermatology. 2011;223:349–55.Google Scholar
  107. Wortsman X, Castro A, Figueroa A. Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016;75:760–7.PubMedGoogle Scholar
  108. Wortsman X, Castro A, Morales C, et al. Sonographic comparison of morphologic characteristics between pilonidal cysts and hidradenitis suppurativa. J Ultrasound Med. 2017;36:2403–18.PubMedGoogle Scholar
  109. Xiao X, He Y, Li C, et al. Nicastrin mutations in familial acne inversa impact keratinocyte proliferation and differentiation through the Notch and phosphoinositide 3-kinase/AKT signalling pathways. Br J Dermatol. 2016;174:522–32.PubMedGoogle Scholar
  110. Xu H, Xiao X, Hui Y, et al. Phenotype of 53 Chinese individuals with nicastrin gene mutations in association with familial hidradenitis suppurativa (acne inversa). Br J Dermatol. 2016;174:927–9.PubMedGoogle Scholar
  111. Xu H, He Y, Hui Y, et al. NCSTN mutations in hidradenitis suppurativa/acne inversa do not influence cytokine production by peripheral blood mononuclear cells. Br J Dermatol. 2017;176:277–9.PubMedGoogle Scholar
  112. Zeeli T, Padalon-Brauch G, Ellenbogen E, et al. Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene. Clin Exp Dermatol. 2015;40:367–72.Google Scholar
  113. Zhang X, Sisodia SS. Acne inversa caused by missense mutations in NCSTN is not fully compatible with impairments in Notch signaling. J Invest Dermatol. 2015;135:618–20.PubMedGoogle Scholar
  114. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–44.PubMedGoogle Scholar
  115. Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177:1401–9.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gerd Plewig
    • 1
  • Bodo Melnik
    • 2
  • WenChieh Chen
    • 3
  1. 1.Department of Dermatology and AllergyLudwig-Maximilian-University MunichMunichGermany
  2. 2.Department of Dermatology, Environmental Medicine and Health TheoryUniversity of OsnabrückOsnabrückGermany
  3. 3.Department of Dermatology and AllergyTechnical University of MunichMunichGermany

Personalised recommendations